Shi Ya-Nan, Gao Hong-Hao, Li Wen-Jun, Chen Jing, Yao Zi-Long, Jing Yu
Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):987-991. doi: 10.7534/j.issn.1009-2137.2017.04.005.
To investigate the clinical manifestation, features of laboratorial examination results and prognosis of patients with Ph/BCR-ABL acute myelogenous leukemia(AML).
The clinical data of 5 AML patients with Ph/BCR-ABL admitted in Department of Hematology of Chinese PLA general hospital from July 2007 to May 2015 were collected and their clinical characteristics, laboatorial examination results and long-term survival were analyzed.
The median age of 5 cases was 39 years old, and 2 cases with splenomegaly. All the cases were assayed for BCR-ABL fusion gene, and 2 of them were accompanied with other molecular abnormalities. In 4 cases, Ph chromosome was not found in one case, and one was with complex karyotype. 3 cases still are live till now and are treated by traditional chemotherapy combined with TKI, and consolidated by allo-HSCT. One case treated by traditional chemotherapy survived for 6 months. And one case treated by traditional chemotherapy combined with TKI survives till to now.
The survival time of Ph/BCR-ABL acute myelogenous leukemia is improved by the traditional chemotherapy combined with TKI and the consolidation with allo-HSCT.
探讨Ph/BCR-ABL急性髓系白血病（AML）患者的临床表现、实验室检查结果特点及预后。
收集2007年7月至2015年5月解放军总医院血液科收治的5例Ph/BCR-ABL AML患者的临床资料，分析其临床特征、实验室检查结果及长期生存情况。
5例患者中位年龄39岁，2例有脾肿大。均检测BCR-ABL融合基因，其中2例伴有其他分子异常。4例患者中1例未发现Ph染色体，1例为复杂核型。3例患者目前仍存活，采用传统化疗联合TKI治疗，并通过异基因造血干细胞移植巩固治疗。1例接受传统化疗的患者存活6个月。1例接受传统化疗联合TKI治疗的患者至今存活。
传统化疗联合TKI并通过异基因造血干细胞移植巩固治疗可提高Ph/BCR-ABL急性髓系白血病患者的生存时间。
